DRI Healthcare Trust (TSE:DHT.UN - Get Free Report)'s share price was up 0.3% on Tuesday . The stock traded as high as C$14.63 and last traded at C$14.56. Approximately 10,381 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 43,911 shares. The stock had previously closed at C$14.51.
Analyst Upgrades and Downgrades
DHT.UN has been the topic of a number of recent analyst reports. CIBC increased their price target on DRI Healthcare Trust from C$16.00 to C$17.00 and gave the stock an "outperform" rating in a research report on Thursday, May 22nd. Royal Bank Of Canada upped their target price on DRI Healthcare Trust from C$17.00 to C$18.00 and gave the stock an "outperform" rating in a research note on Thursday, May 22nd. Finally, National Bankshares increased their target price on DRI Healthcare Trust from C$18.00 to C$18.50 and gave the company an "outperform" rating in a research report on Thursday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, DRI Healthcare Trust has a consensus rating of "Buy" and an average target price of C$19.50.
Check Out Our Latest Stock Analysis on DHT.UN
DRI Healthcare Trust Price Performance
The firm has a market cap of C$808.09 million, a price-to-earnings ratio of 208.00 and a beta of 0.28. The business has a fifty day simple moving average of C$14.36 and a 200 day simple moving average of C$12.96.
DRI Healthcare Trust Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 20th. Shareholders of record on Monday, October 20th will be issued a $0.10 dividend. The ex-dividend date is Monday, September 29th. This represents a $0.40 dividend on an annualized basis and a yield of 2.7%. DRI Healthcare Trust's dividend payout ratio (DPR) is presently 528.57%.
DRI Healthcare Trust Company Profile
(
Get Free Report)
DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DRI Healthcare Trust, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DRI Healthcare Trust wasn't on the list.
While DRI Healthcare Trust currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.